Quick Answer
Coherus Oncology, Inc. reported Net Income Loss of $168.02 million for the year ending 2025.
- Coherus Oncology, Inc. showed an increase of +489.4% in Net Income Loss from 2024 to 2025.
- This data is from Coherus Oncology, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2012 to 2025), Coherus Oncology, Inc.'s Net Income Loss has grown by 608.9%.
- Historical annual values: Fiscal year 2025: $168.02 million | Fiscal year 2024: $28.51 million | Fiscal year 2023: -$237.89 million | Fiscal year 2022: -$291.75 million | Fiscal year 2021: -$287.10 million | Fiscal year 2020: $132.24 million | Fiscal year 2019: $89.83 million | Fiscal year 2018: -$209.34 million | Fiscal year 2017: -$238.17 million | Fiscal year 2016: -$127.34 million | Fiscal year 2015: -$223.26 million | Fiscal year 2014: -$87.13 million | Fiscal year 2013: -$53.64 million | Fiscal year 2012: -$33.02 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: